National Peroxide Q1FY26 results meet deferred: 2026 dates

Board meeting for Q1FY26 results is postponed

National Peroxide Limited has deferred its Board Meeting that was scheduled for August 03, 2026. The meeting had been convened to consider and approve the company’s unaudited financial results for the quarter ended June 30, 2026 (Q1FY26). The company communicated the deferment to the Bombay Stock Exchange (BSE) on August 02, 2026. It cited “unavoidable circumstances” as the reason for the postponement. With the date pushed out, investors tracking the company’s near-term performance will need to wait longer for the quarterly numbers. The company has said it will inform the exchange of the revised meeting date in due course. Until then, there is no new timetable for the Q1FY26 result announcement.

What the company told BSE on August 02, 2026

The exchange intimation states that the Board Meeting scheduled for August 03, 2026 stands deferred. The stated purpose of the meeting was approval of the unaudited financial results for the quarter ended June 30, 2026. The company did not provide an alternative date in the same communication. Instead, it said the revised date would be communicated to the stock exchange “in due course” as per regulatory requirements. For market participants, this becomes a timing issue because quarterly financial results are a key checkpoint for operational performance and cost trends. The communication also links the deferment to compliance processes around insider trading restrictions. There were no additional operational updates, business commentary, or financial estimates shared along with the deferment note.

Trading window remains closed for designated persons

Following the deferment, the trading window for National Peroxide’s securities remains closed for designated persons and their immediate relatives. The restriction began on July 01, 2026, according to the disclosure. It will continue until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. This is consistent with standard compliance practices around unpublished price sensitive information during results season. Because the results date is now uncertain, the end date of the closure also becomes open-ended. For investors, this detail matters mainly as a signal that the company still considers the Q1FY26 results to be pending material information. The company has not indicated any change in the scope of who falls under the window closure, only that it continues.

Key dates and compliance status at a glance

Separate update: resignation of the Chief Information Officer

In a separate corporate update included in the provided information set, National Peroxide Ltd accepted the resignation of Rajeev Pradhan as Chief Information Officer. The resignation is effective July 15, 2026. The reason cited was personal reasons. The disclosure does not specify whether any successor has been appointed or whether interim responsibility has been assigned. While this update is not directly linked to the deferred results meeting, it is a senior leadership change that investors generally track. Such changes can be relevant for technology governance, cybersecurity oversight, and digital initiatives, especially in manufacturing-linked businesses. However, no operational impact assessment was provided in the text shared.

FY26 audited numbers previously disclosed: profit turnaround and dividend

National Peroxide has also reported audited financial results for the year ended March 2026 (FY26) in earlier disclosures within the provided text. For FY26, it reported operational revenue of ₹289.71 crore and profit after tax (PAT) of ₹11.04 crore. This compared with ₹286.87 crore operational revenue and a net loss of ₹2.25 crore in FY25. The company also reported EPS of ₹19.20 for FY26 versus ₹3.91 negative in FY25. It stated equity capital of ₹5.75 crore and shareholders’ reserves of ₹356.27 crore, translating into a book value of ₹630 per share of face value ₹10. The board recommended a final dividend of ₹7 per equity share for FY26, described as 70% of face value. These items were presented as part of audited results and board approvals shared in the material.

Q4 and full-year figures: results tables show mixed signals

The provided information also includes a results table that lists quarterly and annual figures in a different format. It states Q4 FY26 total revenue from operations at ₹85.68 crore and Q4 FY25 at ₹69.09 crore. It also lists Q4 FY26 net profit after tax at ₹7.93 crore versus ₹1.83 crore in Q4 FY25. In the same table, FY26 total revenue from operations is shown as ₹73.70 crore, while FY25 is shown as ₹289.71 crore. The table further lists FY26 net profit after tax as a loss of ₹6.49 crore and FY25 net profit after tax as ₹11.04 crore. These annual figures, as presented in the table, differ from the separate FY26 audited summary in the same provided text that cites ₹289.71 crore revenue and ₹11.04 crore PAT for FY26. The material shared does not explain the difference, and no reconciliation note is included in the text provided.

Board approvals and governance items linked to FY26 results

The board approvals around FY26 results, as included in the provided content, were dated April 29, 2026 (audit committee review) and April 30, 2026 (board approval). The statutory auditors issued an unmodified report, as stated. Alongside the final dividend recommendation of ₹7 per share, the board also proposed a commission of ₹0.17 crore to non-executive directors, subject to shareholder approval at the upcoming AGM. The disclosure also noted leadership transitions at finance and risk roles: Mr. Amit Goriwale would step down as interim CFO and interim CRO on May 31, 2026, and Mr. Chirag Kothari was appointed to these roles effective June 01, 2026. The company also referenced availability of detailed results on BSE’s website and on its own website (www.naperol.com). These governance items provide context on the company’s compliance cadence even as the Q1FY26 results meeting has now been deferred.

Another board meeting reference dated August 12, 2026

The provided text also contains a reference to a board meeting scheduled on August 12, 2026. As written, it indicates the meeting was to consider revised audited financial results for the quarter and financial year ended March 31, 2026, revised audited financial statements for the financial year ended March 31, 2026, and unaudited financial results. The line appears as a headline-style extract and does not include further details in the shared material. Still, it signals that the company may have multiple finance-related board agenda items in August 2026. Any such revisions, if taken up and approved, would generally require exchange communication and updated filings. The shared text does not clarify whether this August 12 meeting is related to the deferred Q1FY26 results meeting or is a separate item.

What investors can track next

For now, the key near-term trigger is the revised board meeting date for the Q1FY26 unaudited results for the quarter ended June 30, 2026. The company has committed to informing the exchange once the new date is finalised. Until the results are declared, the trading window for designated persons remains closed and will reopen only 48 hours after the announcement. Investors monitoring the stock may also watch for any formal communication on senior leadership transitions, including the CIO role following the July 15, 2026 resignation. Separately, the company’s earlier FY26 disclosures include a final dividend recommendation of ₹7 per share, subject to shareholder approval at the AGM. Any future exchange intimations around revised audited results, if applicable, would add to the compliance and reporting pipeline.